Shenzhen Sincere Bio Announces Completion of RMB 200 Million Series A+ Financing Led by Youshan Capital, with HaoYue Capital as Exclusive Financial Advisor

VCBeat learned recently,Shenzhen Xianbo Biotechnology Co., Ltd. (hereinafter referred to as "Xianbo Bio"), which focuses on the development of innovative immunotherapy, has completed a RMB 200 million Series A+ round of financing. This round of financing was led by Youshan Capital, with participation from Oriza Holdings, PagodaTree Partners, and Shenzhen Guochuang Qinzhi Great Health Industry Angel Investment Partnership (Limited Partnership). HAOYUE CAPITAL served as the financial advisor for this round of financing.

CEO of Shenzhen Xianbo Biotechnology Co., Ltd., Dr. Cao ZhuoxiaoExpressed gratitude to all investors for their recognition and support. The Xianbo team will continue to strive forward, advancing the clinical development of core pipelines, including focusing on expanding...CAR-NK Cell TherapyThe treatment potential for different indications; actively promoting competitiveSolid Tumor ProjectDevelopment; WillIn Vivo Cell Therapy Technology Based on mRNA TechnologyEnter the clinical validation stage; at the same time, continue to deepen cooperation with partners, and look forward to launching high clinical value products as soon as possible through the above multi-faceted efforts for the benefit of patients.

Chen Shiyou, Chairman of Youshan CapitalExpressed delight in leading the current round of financing for Shenzhen Xianbo Biotechnology Co., Ltd. Youshan Capital is optimistic about immune cell therapy becoming one of the significant treatment methods, especially universal immune cell therapy, which will greatly improve accessibility. Beyond hematological tumors, it also holds broad therapeutic prospects in diseases such as autoimmune disorders, antiviral treatments, and anti-aging. We look forward to the Xianbo team bringing revolutionary cell therapy products to patients!

Oriza Holdings Partner Zhao QunOriza Holdings stated that it is optimistic about the current technological development prospects and clinical application potential of cell therapy. It continues to focus on and invest in next-generation cell technology products with better efficacy, lower costs, and broader applications. This investment reflects confidence in Shenzhen Xianbo Biotechnology Co., Ltd., which focuses on industry pain points and has been making significant progress in developing and exploring products for allogeneic and solid tumor fields. The company has quickly built up a highly competitive industry barrier, advancing its pipeline into the clinical stage through multiple technology platforms.

Founder of PagodaTree Partners, Lu YancenShenzhen Xianbo Biotechnology Co., Ltd., a clinical-stage cell and gene therapy biotechnology company, possesses leading technological innovation, commercialization, and comprehensive international capabilities. PagodaTree Partners, as a key investor in this round, recognizes, trusts, and will continue to support Xianbo Biotechnology. Through this investment, both parties will further leverage synergies to jointly expand and deepen strategic cooperation in areas such as innovative biotechnology investment, internationalization, and clinical resources.

Chairman of Qinzhi Capital, Tang DajieRepresentatives stated that the Xianbo Biotech team has demonstrated highly efficient execution and strong resource integration capabilities in R&D, CMC, clinical, and commercialization aspects, which is very rare among startups in China. The company has developed rapidly in recent years. We look forward to these pipelines achieving more impressive clinical results and reducing production costs through mature and stable CMC capabilities, making cell therapy accessible and benefiting a broader patient population.

Founder and CEO of HAOYUE CAPITAL, Liu HaoWe are honored to serve as the exclusive financial advisor for Shenzhen Xianbo Biotechnology Co., Ltd. in this round of financing and assist the company in completing this funding. We believe that the second half of China's cell therapy industry has arrived, and the model combining industry leaders with this innovative technology will carve out a significant position in the field. In an era where the commercialization of cell therapy is being questioned, the empowerment of industry leaders will help biotech companies deliver strong results when they reach the commercial stage in the future.

Shenzhen Xianbo Biotechnology Co., Ltd. is a cell therapy biotechnology company at the clinical development stage. The company's universal NK platform features an innovative, proprietary CAR structure design and possesses mature and stable CMC capabilities for large-scale production of universal NK cells. Its first CAR-NK pipeline, SNC103, achieved positive results in the IIT phase and has entered Phase I clinical trials. SNC109, a dual CAR-T cell therapy with a self-developed dual-arm BiTE armor based on another core platform, was granted "Orphan Drug Designation" by the FDA for the treatment of malignant gliomas. This product has also received clinical tacit approval from China’s CDE and is about to initiate Phase I clinical trials. Additionally, Xianbo has formed a strategic partnership with ORNA, a U.S.-based emerging biotechnology company, to develop next-generation universal in vivo cell therapy products based on circular mRNA and targeted delivery platforms. This technology is expected to become another disruptive form of universal cell therapy drugs, showing broad potential applications in oncology, autoimmune diseases, and other therapeutic areas.

Youshan Capital was founded in 2020, jointly established with well-known professional institutions such as CICC Capital, Shenzhen Capital Group, private listed companies/shareholders, and market-oriented mother funds. It currently manages a fund size of 13.2 billion yuan. The focus is on investing in growth enterprises in technology-empowered industries such as high-end equipment manufacturing, new energy, healthcare, and artificial intelligence.

PagodaTree Partners was founded in 2019 as a boutique private equity fund manager specializing in the healthcare and technology innovation industries. It was awarded "Top 10 Emerging Venture Capital Institutions in China" by the 2022 ChinaVenture Awards and ranked among the "Top 50 Best VC Funds in 2023" by the Mother Fund Research Center. Adhering to the philosophy of "Pudao for the World," the firm fulfills its social responsibilities. Its investors include leading market-oriented mother funds and family offices in China, as well as renowned institutional investors and entrepreneurs. The core management team hails from top-tier international investment institutions and possesses extensive industry resources and an international perspective in the healthcare and technology innovation sectors. The team has rich experience in mergers and acquisitions within China and cross-border transactions, growth-stage and early-stage investments, capital markets, and operational management. PagodaTree Partners focuses on healthcare and life sciences, technological innovation, and related cutting-edge interdisciplinary fields. It actively engages in special investment opportunities, collaborates deeply with entrepreneurs, co-creates value, and builds the PagodaTree Partners ecosystem. Offices are located in Beijing, Shanghai, Hong Kong, Boston, and Seattle.

Oriza Holdings is an early-stage equity investment platform under Oriza Holdings Corporation, operating in a market-oriented and professional manner. It focuses on investment opportunities in start-ups and early growth-stage enterprises within the technology and healthcare sectors. The total scale of the fund is approximately 6.5 billion RMB, including both VC funds and angel funds targeting specific regions. Oriza Holdings' investment style emphasizes early-stage involvement, a preference for technology, and a commitment to promises. It is dedicated to injecting growth momentum into start-up companies and growing together with entrepreneurs.

Shenzhen Qianhai Qinzhi International Capital Management Co., Ltd. (P1030072), established in October 2015, gathers senior industry professionals from Shenzhen Capital Group, Roche, GSK, BMS, Abbvie, AstraZeneca, and BGI Life, as well as research experts from renowned universities both domestically and internationally. Guided by the value concept of "investment returning to the real economy, capital serving the industry," Qinzhi Capital has laid out an industrial ecosystem with a focus on original investment and value investment. By connecting with industry and technology platforms such as Shenzhen JiYin Biomedical Transformation Research Institute and the National Innovation Center for High-Performance Medical Devices, Qinzhi Capital "co-entrepreneurs" with industry teams, using capital power to facilitate the industrialization of scientific research achievements. Qinzhi Capital currently has offices in Shenzhen, Shanghai, and Hong Kong, and has initiated the establishment of nearly forty RMB and USD funds. Representative investment cases of Qinzhi Capital include: Akeso Biopharma, AsiaPharm, Adlai Nortye,菲鹏生物,荃信生物,亦诺微,亿航生物,嘉树医疗,三迭纪,北芯生命,海和药物,赛赋医药,东阳光药,嘉越医药.